{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:38Z","timestamp":1787010158014,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Bureau of Jiangjin District","award":["Y2019061"],"award-info":[{"award-number":["Y2019061"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) decrease the rate of rebleeding following endoscopic hemostatic therapy in patients with bleeding peptic ulcers. This study compares the efficacy of oral omeprazole vs intravenous omeprazole in decrease of rebleeding of peptic ulcer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>The present study was authorized by the local research ethics committee of Jiangjin District Central Hospital (2020120987) and informed consent was obtained from all patients. All adult patients who were admitted to medical emergency rooms of Jiangjin District Central Hospital due to upper gastrointestinal bleeding (as evidenced by hematemesis, melena or hematochezia) were considered for inclusion in the study. Endoscopy was performed within 24\u200ahours after admission. Patients older than 18\u200ayears with successful endoscopic therapy of high risk ulcers [defined as active bleeding (Forrest IA, IB), non-bleeding visible vessel (NBVV, Forrest IIA) or adherent clots (Forrest IIB)] were enrolled. Patients with low risk ulcers (clean base, ulcers with a simple washable clot), suspicious malignant ulcer, bleeding tendency, uremia, liver cirrhosis, Mallory Weiss tear or already on PPI as an outpatient were excluded from study. All were managed endoscopically by injecting 5\u201330\u200aml of epinephrine (diluted 1:10000) around the ulcer crater. Cavitations or flattening of bleeding vessel and disappearance of NBVV was considered as established homeostasis. A biopsy was taken from antrum for evaluating Helicobacter pylori infection. Patient with unsuccessful endoscopic therapy were not enrolled and were referred to general surgeon. Information on demography, history of previous upper gastrointestinal bleeding, NSAID or ASA ingestion, ulcer location, bleeding stigmata and blood transfusion volume at entry were recorded in all patients. In the oral omeprazole group, the patients received 40\u200amg omeprazole orally twice daily for 72\u200ahours. In intravenous omeprazole group, they received omeprazole 80\u200amg bolus and then 8\u200amg\/hour infusion for 48\u201372\u200ahours. Then, all patients received omeprazole 20\u200amg orally for 30\u200adays. On the day of discharge Helicobacter pylori infected patients received standard regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Figure 1 showed the primary and secondary end points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Intravenous administration of PPIs has limitations. They are expensive, require a dedicated intravenous line, need nursing supervision and hospital admission. So, it would be reasonable to prescribe oral PPIs to patients with high risk bleeding ulcers provided that it is as effective as its intravenous counterpart. Oral PPIs have a high bioavailability. Its effect initiates one hour after ingestion and the maximal plasma concentration is achieved after 2\u20133\u200ahours. However, there are few studies comparing oral and intravenous PPI in decreasing risk of rebleeding in peptic ulcer patients. More high quality randomized controlled trials are still necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration number:<\/jats:title>\n                    <jats:p>researchregistry 6588<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000025136","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:56:24Z","timestamp":1617843384000},"page":"e25136","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous versus oral omeprazole on patients with high risk bleeding peptic ulcers"],"prefix":"10.1097","volume":"100","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panya","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-172X","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mayocp.2019.01.022","article-title":"Upper gastrointestinal bleeding: etiologies and management","volume":"94","author":"Kamboj","year":"2019","journal-title":"MAYO CLIN PROC"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.amjmed.2018.12.009","article-title":"Diagnosis and treatment of peptic ulcer disease","volume":"132","author":"Kavitt","year":"2019","journal-title":"Am J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"390","author":"Lanas","year":"2017","journal-title":"Lancet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.3748\/wjg.v26.i35.5302","article-title":"Epidemiology of perforating peptic ulcer: A population-based retrospective study over 40\u200ayears","volume":"26","author":"Dadfar","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.2010.04563.x","article-title":"The changing face of hospitalisation due to gastrointestinal bleeding and perforation","volume":"33","author":"Lanas","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/apt.12380","article-title":"Review article: historic changes of Helicobacter pylori-associated diseases","volume":"38","author":"Sonnenberg","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cgh.2008.08.016","article-title":"Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials","volume":"7","author":"Laine","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1572-0241.2006.01023.x","article-title":"Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials","volume":"102","author":"Marmo","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14740\/gr1011w","article-title":"Once versus twice-daily oral proton pump inhibitor therapy for prevention of peptic ulcer rebleeding: a propensity score-matched analysis","volume":"11","author":"Ayoub","year":"2018","journal-title":"Gastroenterology Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jgh.13822","article-title":"Peptic ulcer bleeding patients with Rockall scores >\/=6 are at risk of long-term ulcer rebleeding: A 3.5-year prospective longitudinal study","volume":"33","author":"Yang","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"386","DOI":"10.23736\/S0026-4806.18.05705-1","article-title":"The appropriate use of proton-pump inhibitors","volume":"109","author":"Savarino","year":"2018","journal-title":"Minerva Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM200008033430501","article-title":"Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers","volume":"343","author":"Lau","year":"2000","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archinte.158.1.54","article-title":"A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy","volume":"158","author":"Lin","year":"1998","journal-title":"Arch Intern Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.giec.2011.07.012","article-title":"Endoscopic therapy for severe ulcer bleeding","volume":"21","author":"Kovacs","year":"2011","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"290","DOI":"10.7196\/SAMJ.5457","article-title":"The efficacy of endoscopic therapy in bleeding peptic ulcer patients","volume":"102","author":"Levin","year":"2012","journal-title":"S Afr Med J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0016-5085(78)90352-9","article-title":"Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage","volume":"74","author":"Green","year":"1978","journal-title":"Gastroenterology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2036.2005.02391.x","article-title":"Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding","volume":"21","author":"Bardou","year":"2005","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:20:03Z","timestamp":1746325203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025136"}},"subtitle":["A prospective randomized clinical trial protocol"],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":18,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025136","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"2021-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}